Latest News

Democrats are widely expected to retake one or both houses of Congress, creating potential friction points for Wall Street.

Balance sheet discipline, not just the pace of new data centers, is what the call suggests could protect DigitalOcean's margins if demand cools.

Bausch Health stock surged 25% after Q3 results, a raised outlook and a first $1 billion EBITDA quarter. Here is what drove the rally and what could slow it next.

Steady fees, rising investor participation, and a growing dividend make Broadridge’s latest quarter worth a closer look.

Rising memory chip costs are squeezing margins even as a massive device base opens new revenue paths.

Conversions now account for over a third of new rooms, unlocking growth in markets where independent hotels still dominate.

Ferrari's pricing power rests on exclusive client experiences rather than volume, so the durability of that moat is the question long-term holders must weigh.

The cyclical slump in the chemical industry didn't affect one of its top names in the third quarter.

Sysco's margin story hinges on whether its fiscal 2029 efficiency targets hold as restaurant traffic continues to fall.

It's happened in around one year in five since 1950. How did the next two months usually go?

BBB Foods’ newer stores start stronger and ramp faster than older ones, which could mean quicker payback on every opening.

New software tools in building components offer a growth lever beyond pricing power, positioning the company for momentum when housing rebounds.

Cost discipline and Asian wealth inflows give HSBC room to boost shareholder returns without sacrificing growth.

Healthcare inflation is pressuring workers' compensation claims across the industry, testing whether Hartford's pricing discipline can protect margins.

Aerospace custom wins are tripling while data center expansion accelerates, signaling structural growth beyond automotive.

Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results. Net income totaled $126.8 million, compare

Cricut (NASDAQ:CRCT) reported third-quarter 2026 revenue of $188.6 million, up approximately 11% from a year earlier, as new connected-machine launches and platform growth supported results. Net income rose to $27.8 million, or $0.13 per diluted share, from $20.5 million, or $0.10 per share, in the

Crexendo (NASDAQ:CXDO) reported third-quarter 2026 revenue of $25.2 million, up 44% from a year earlier, as the company said it reached a $100 million annualized revenue run rate. The communications software and services provider also reported GAAP net income of $1.1 million, or $0.03 per diluted sh

O'Reilly Automotive (NASDAQ:ORLY) executives highlighted the company’s promote-from-within culture, metropolitan distribution network and inventory availability strategy as central drivers of its market-share ambitions during a recent investor presentation. Chief Executive Officer Brad Beckham said

CeriBell (NASDAQ:CBLL) reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring S

Booking (NASDAQ:BKNG) reported third-quarter results that exceeded the high end of its guidance for room nights, gross bookings, adjusted revenue and adjusted EBITDA, while outlining a more cautious outlook for the fourth quarter amid moderating international travel demand and disruptions tied to th

Denali Therapeutics (NASDAQ:DNLI) reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch. The company s

Amdocs (NASDAQ:DOX) reported fourth-quarter and full-year fiscal 2026 results in line with its guidance while outlining a fiscal 2027 outlook that reflects a significant expected revenue and profit impact from its situation with T-Mobile. President and Chief Executive Officer Shimie Hortig said the

Alamar Biosciences (NASDAQ:ALMR) reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program, or TAP, services quarter to date. The precision proteomics company also raised its full-year revenue

Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for dialysis-focused drug XPHOZAH. President and Chief Executive Officer Mike Raab said the company’s two fir